Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism
Qiangnu Zhang,Teng Wei,Jin Wen,Lesen Yan,Lulin Shi,Siqi Zhu,Yu Bai,Yuandi Zeng,Zexin Yin,Jilin Yang,Wenjian Zhang,Meilong Wu,Yusen Zhang,Gongze Peng,Stephanie Roessler,Liping Liu
DOI: https://doi.org/10.1016/j.jhep.2023.10.024
IF: 25.7
2023-10-31
Journal of Hepatology
Abstract:Background & Aims The role of SLC25A15, a critical component of the urea cycle, in hepatocellular carcinoma (HCC) progression remains poorly understood. This study investigated the impact of SLC25A15 on HCC progression and its mechanisms. Methods We systematically investigated the function of SLC25A15 in HCC progression using large-scale data mining and cell, animal, and organoid models. Furthermore, we discussed involvement in reprogramming glutamine metabolism. Results SLC25A15 expression was significantly decreased in HCC tissues, and patients with low SLC25A15 levels had a poorer prognosis. Hypoxia-exposed HCC cells or tissues had lower SLC25A15 expression. A positive correlation between HNF4A, a transcription factor suppressed by hypoxia, and SLC25A15 was observed in both HCC tissues and cells. Modulating HNF4A levels altered SLC25A15 mRNA levels. SLC25A15 upregulated SLC1A5, increasing glutamine uptake. The reactive metabolic pathway of glutamine was increased in SLC25A15-deficient HCC cells, providing energy for HCC progression through additional lipid synthesis. Ammonia accumulation due to low SLC25A15 levels suppressed the expression of OGDHL, a switch gene that mediates SLC25A15 deficiency–induced glutamine metabolism reprogramming. SLC25A15-deficient HCC cells were more susceptible to glutamine deprivation and glutaminase inhibitors. Intervening in glutamine metabolism increased SLC25A15-deficient HCC cells' response to anti-PD-L1 treatment. Conclusion SLC25A15 is hypoxia-responsive in HCC, and low SLC25A15 levels result in glutamine reprogramming through SLC1A5 and OGDHL regulation, promoting HCC progression and regulating cell sensitivity to anti-PD-L1. Interrupting the glutamine-derived energy supply is a potential therapeutic strategy for treating SLC25A15-deficient HCC. Impact and implications We first demonstrated the tumour suppressor role SLC25A15 in HCC and showed that its deficiency leads to glutamine metabolism reprogramming to promote HCC development. SLC25A15 can serve as a potential biomarker for guiding the development of precision therapeutic strategies aimed at targeting glutamine deprivation. Furthermore, This study highlights that the combined use of an inhibitor of glutamine utilization can enhance the sensitivity of low SLC25A15 HCC to anti-PD-L1 therapy.
gastroenterology & hepatology